BioStock: Abliva on the IND-approval from FDA

A few weeks ago, the US Food and Drug Administration approved Abliva’s Investigational New Drug application for KL1333, enabling the start of a registrational phase II/III study with first patients due to be recruited in 2022. BioStock reached out to Magnus Hansson, CMO & VP Preclinical and Clinical Development, for a comment.

Read the interview with Magnus Hansson at biostock.se:

https://www.biostock.se/en/2021/12/abliva-on-the-ind-approval-from-fda/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/